So let’s forget the extremes, and talk about what comes in the middle. First, AstraZeneca did attempt to demonstrate leadership in an industry notorious for being skittish on social media. Twitter can be especially unnerving for pharmaceutical companies, and moderating a wide-open chat would make most of them break out in to a cold sweat. (more…)
Archive for the ‘Pharmaceuticals’ Category
I’d planned on writing a brilliant post after last week’s 9th Annual ePharma Summit in Philadelphia. I wanted to explain why this statement made by one of the conference’s speakers always makes me bristle.
“Content remains King.”
First, most of us have heard some version of the content-is-king quip. Few of us understand what it really means. So many seem clueless about the power of content. Hardly anyone in pharma knows how to do it well. Finally, and most important—and I did say something along this line at the conference: Content without context is just a bunch of rubbish. (And, by the way, bad content without context should be rammed down someone’s throat.) (more…)
The FDA goes to great lengths to ensure drug makers disclose side effects. This “fair balance” language in ads and marketing materials is intended to ensure patients know the risks involved in taking a medication, and have all the information they need to make an informed decision with the help of their physician. And, to keep drug companies from making bold claims about a drug while minimizing risks.
All of this makes sense.
Except: What if disclosing side effects actually causes a patient to experience them, thus making a patient sicker and ultimately making the drug less effective?
It’s called the “nocebo effect,” the opposite of the “placebo effect.” A nocebo response occurs when the suggestion of a negative effect actually leads to a patient experiencing that side effect. It’s for real and has repeatedly been scientifically proven: (more…)